Literature DB >> 16106356

Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy.

Giovanni Piedimonte1, Gabriele Renzetti, Alexander Auais, Antonio Di Marco, Salvatore Tripodi, Franco Colistro, Alberto Villani, Vincenzo Di Ciommo, Renato Cutrera.   

Abstract

Respiratory syncytial virus (RSV) infection is the most common cause of bronchiolitis in infants and an important risk factor for the development of recurrent wheezing and asthma. Cysteinyl leukotrienes were implicated in the pathophysiology of these diseases, and are being targeted for their diagnosis and therapy. We measured urinary leukotriene E4 (LTE4) in infants with RSV bronchiolitis in comparison with controls without respiratory infection, and investigated whether medical and family history, age, and passive exposure to tobacco smoke are related to urinary leukotriene excretion. We studied 33 infants with bronchiolitis and 25 controls, 1-12 months of age. Demographic and historical data were obtained from informed-consent forms and questionnaires completed by the parents. RSV was detected in nasal secretions by enzyme-linked immunoassay. Urine samples were collected on day of admission and were analyzed for LTE4 with an enzyme-linked immunoassay. Urinary LTE4 was 8-fold higher in infants with bronchiolitis than in controls. Leukotriene excretion was significantly higher in infected infants <6 months of age with a medical history of eczema or dry cough and/or family history of asthma. Multivariate analysis revealed that eczema and dry cough are independently associated with high LTE4 excretion during bronchiolitis. Exposure to tobacco smoke did not affect urinary LTE4. Our study shows that leukotriene synthesis during bronchiolitis is particularly elevated in younger infants with an atopic/asthmatic background. Urinary LTE4 may become a valuable, noninvasive marker for the identification of patients who will benefit most from therapy with leukotriene modifiers for management of bronchiolitis. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16106356     DOI: 10.1002/ppul.20285

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  14 in total

1.  Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus.

Authors:  Junyan Han; Yi Jia; Katsuyuki Takeda; Yoshiki Shiraishi; Masakazu Okamoto; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Crit Care Med       Date:  2010-05-04       Impact factor: 21.405

Review 2.  The role of the respiratory syncytial virus in airway syndromes in childhood.

Authors:  Mark L Everard
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

3.  Urinary leukotriene E4, obesity, and adenotonsillar hypertrophy in Chinese children with sleep disordered breathing.

Authors:  Yuelin Shen; Zhifei Xu; Kunling Shen
Journal:  Sleep       Date:  2011-08-01       Impact factor: 5.849

Review 4.  Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity.

Authors:  Paul M Brown; Dana L Schneeberger; Giovanni Piedimonte
Journal:  Paediatr Respir Rev       Date:  2015-05-23       Impact factor: 2.726

Review 5.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

6.  A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye.

Authors:  Alla Musiyenko; Lucia Correa; Nicholas Stock; John H Hutchinson; Daniel S Lorrain; Gretchen Bain; Jilly F Evans; Sailen Barik
Journal:  Clin Vaccine Immunol       Date:  2009-09-16

7.  Airway brush cells generate cysteinyl leukotrienes through the ATP sensor P2Y2.

Authors:  Saltanat Ualiyeva; Nils Hallen; Yoshihide Kanaoka; Carola Ledderose; Ichiro Matsumoto; Wolfgang G Junger; Nora A Barrett; Lora G Bankova
Journal:  Sci Immunol       Date:  2020-01-17

Review 8.  Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets.

Authors:  Mary K McCarthy; Jason B Weinberg
Journal:  Mediators Inflamm       Date:  2012-05-15       Impact factor: 4.711

9.  Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.

Authors:  Donald H Arnold; Sara L Van Driest; Theodore F Reiss; Jennifer C King; Wendell S Akers
Journal:  J Clin Pharmacol       Date:  2020-09-22       Impact factor: 3.126

10.  The cysteinyl leukotriene 3 receptor regulates expansion of IL-25-producing airway brush cells leading to type 2 inflammation.

Authors:  Lora G Bankova; Daniel F Dwyer; Eri Yoshimoto; Saltanat Ualiyeva; John W McGinty; Hannah Raff; Jakob von Moltke; Yoshihide Kanaoka; K Frank Austen; Nora A Barrett
Journal:  Sci Immunol       Date:  2018-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.